<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04983745</url>
  </required_header>
  <id_info>
    <org_study_id>WCC 2020-002</org_study_id>
    <nct_id>NCT04983745</nct_id>
  </id_info>
  <brief_title>Niraparib and Dostarlimab in HRD Solid Tumors</brief_title>
  <acronym>DIDO</acronym>
  <official_title>A Phase II Trial of Niraparib and Dostarlimab Combination Therapy in Patients With Somatic Homologous Recombination Deficient Advanced or Metastatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-arm, Phase 2 study which will evaluate the efficacy and safety&#xD;
      of niraparib and dostarlimab (TSR-042) combination in patients with metastatic, recurrent, or&#xD;
      unresectable solid tumor with a pathogenic, or presumed pathogenic, somatic homologous&#xD;
      recombination deficiency (HRD) gene mutation&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">August 2025</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>2 years</time_frame>
    <description>defined as the percentage of patients with CR or PR, as assessed by RECIST v.1.1 criteria using investigator review.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR)</measure>
    <time_frame>16 weeks</time_frame>
    <description>defined as the percentage of patients with CR, PR or SD, as assessed by RECIST v.1.1 criteria using investigator's review at 16 weeks</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Homologous Recombination Deficient Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>niraparib and dostarlimab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination drug</intervention_name>
    <description>niraparib and dostarlimab combination</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Metastatic, recurrent, or unresectable solid tumor with a pathogenic, or presumed&#xD;
             pathogenic, somatic mutation of one of the following homologous recombination&#xD;
             deficiency (HRD) gene mutations:&#xD;
&#xD;
             • BRCA1, BRCA2, ATM, RAD51B, RAD51C, RAD54L, RAD51D, FANC/BRIP1, FANCI, FANCL,&#xD;
             FANCN(PALB2), BARD1, CHEK1, CHEK2, CDK12, or PPP2R2A.&#xD;
&#xD;
          2. Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status&#xD;
             of ≤ 1&#xD;
&#xD;
          3. Participant must be ≥ 18 years of age&#xD;
&#xD;
          4. Participant must have adequate organ function, defined as follows:&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1,500/µL&#xD;
&#xD;
               -  Platelets ≥ 100,000/µL&#xD;
&#xD;
               -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or calculated creatinine&#xD;
                  clearance ≥ 60mL/min using the Cockcroft-Gault equation&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x ULN (≤2.0 in patients with known Gilberts syndrome) OR&#xD;
                  direct bilirubin ≤ 1 x ULN&#xD;
&#xD;
               -  Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x ULN unless liver&#xD;
                  metastases are present, in which case they must be ≤ 5 x ULN&#xD;
&#xD;
               -  International normalized ratio (INR) or prothrombin time (PT) ≤1.5× ULN unless&#xD;
                  patient is receiving anticoagulant therapy as long as PT or partial&#xD;
                  thromboplastin (PTT) is within therapeutic range of intended use of&#xD;
                  anticoagulants. Activated partial thromboplastin time (aPTT) ≤1.5× ULN unless&#xD;
                  patient is receiving anticoagulant therapy as long as PT or PTT is within&#xD;
                  therapeutic range of intended use of anticoagulants&#xD;
&#xD;
          5. Participant must agree to not donate blood during the study or for 90 days after the&#xD;
             last dose of study treatment.&#xD;
&#xD;
          6. Female participant has a negative serum pregnancy test within 72 hours prior to taking&#xD;
             study treatment if of childbearing potential and agrees to use a highly effective&#xD;
             method of contraception from screening through 180 days after the last dose of study&#xD;
             treatment, or is of non-childbearing potential. Non-childbearing potential is defined&#xD;
             as follows (by other than medical reasons):&#xD;
&#xD;
               -  ≥45 years of age and has not had menses for &gt;1 year&#xD;
&#xD;
               -  Patients who have been amenorrhoeic for &lt;2 years without history of a&#xD;
                  hysterectomy and oophorectomy must have a follicle stimulating hormone value in&#xD;
                  the postmenopausal range upon screening evaluation&#xD;
&#xD;
               -  Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation.&#xD;
                  Documented hysterectomy or oophorectomy must be confirmed with medical records of&#xD;
                  the actual procedure or confirmed by an ultrasound. Tubal ligation must be&#xD;
                  confirmed with medical records of the actual procedure, otherwise the patient&#xD;
                  must be willing to use an adequate barrier method throughout the study, starting&#xD;
                  with the screening visit through 180 days after the last dose of study treatment.&#xD;
                  See Section 5.4 for a list of acceptable birth control methods. Information must&#xD;
                  be captured appropriately within the site's source documents. Note: Abstinence is&#xD;
                  acceptable if this is the established and preferred contraception for the&#xD;
                  patient.&#xD;
&#xD;
        h. Male participant agrees to use a highly effective method of contraception (see Section&#xD;
        5.4 for a list of acceptable birth control methods) starting with the first dose of study&#xD;
        treatment through 180 days after the last dose of study treatment. Note: Abstinence is&#xD;
        acceptable if this is the established and preferred contraception for the patient.&#xD;
&#xD;
        i. Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral&#xD;
        therapy with documented undetectable viral load and CD 4 count of &gt;350 within 6 months of&#xD;
        the first dose of study treatment are eligible for this trial.&#xD;
&#xD;
        j. If an appropriate archival tumor tissue sample is not available, patient is willing to&#xD;
        undergo a pre-treatment tumor biopsy.&#xD;
&#xD;
        k. Participant must be able to understand the study procedures and agree to participate in&#xD;
        the study by providing written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participant must not be simultaneously enrolled in any interventional clinical trial&#xD;
&#xD;
          2. Patients with the following malignancies will be excluded:&#xD;
&#xD;
               -  Prostate cancer&#xD;
&#xD;
               -  Ovarian, breast, and pancreatic patients with known germline BRCA1 or BRCA2&#xD;
                  mutation&#xD;
&#xD;
               -  Platinum sensitive ovarian cancer (defined as recurrence &gt; 6 months from last&#xD;
                  platinum agent), unless platinum intolerant.&#xD;
&#xD;
          3. Participant must not have had major surgery ≤ 3 weeks prior to initiating protocol&#xD;
             therapy and participant must have recovered from any surgical effects.&#xD;
&#xD;
          4. Participant must not have received investigational therapy ≤ 4 weeks, or within a time&#xD;
             interval less than at least 5 half-lives of the investigational agent, whichever is&#xD;
             shorter, prior to initiating protocol therapy.&#xD;
&#xD;
          5. Participant has had radiation therapy encompassing &gt;20% of the bone marrow within 2&#xD;
             weeks; or any radiation therapy within 1 week prior to Day 1 of protocol therapy.&#xD;
&#xD;
          6. Participant must not have a known hypersensitivity to niraparib and dostarlimab&#xD;
             components or excipients.&#xD;
&#xD;
          7. Participant must not have received a transfusion (platelets or red blood cells) ≤ 4&#xD;
             weeks prior to initiating protocol therapy.&#xD;
&#xD;
          8. Participant must not have received colony stimulating factors (eg, granulocyte&#xD;
             colony-stimulating factor, granulocyte macrophage colony stimulating factor, or&#xD;
             recombinant erythropoietin) within 4 weeks prior initiating protocol therapy.&#xD;
&#xD;
          9. Participant has had any known Grade 3 or 4 anemia, neutropenia or thrombocytopenia due&#xD;
             to prior chemotherapy that persisted &gt; 4 weeks and was related to the most recent&#xD;
             treatment.&#xD;
&#xD;
         10. Participant must not have any known history of myelodysplastic syndrome (MDS) or acute&#xD;
             myeloid leukemia (AML)&#xD;
&#xD;
         11. Participant must not have a serious, uncontrolled medical disorder, nonmalignant&#xD;
             systemic disease, or active, uncontrolled infection. Examples include, but are not&#xD;
             limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial&#xD;
             infarction, uncontrolled major seizure disorder, unstable spinal cord compression,&#xD;
             superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining&#xD;
             informed consent&#xD;
&#xD;
         12. Participant must not have had diagnosis, detection, or treatment of another type of&#xD;
             cancer ≤ 2 years prior to initiating protocol therapy (except basal or squamous cell&#xD;
             carcinoma of the skin and cervical cancer that has been definitively treated)&#xD;
&#xD;
         13. Participant must not have known leptomeningeal disease, carcinomatous meningitis,&#xD;
             symptomatic brain metastases, or radiologic signs of CNS hemorrhage.&#xD;
&#xD;
             • Patients with a history of brain metastases may be enrolled if the metastases are&#xD;
             fully treated with either resection or irradiation, the patient is asymptomatic for 4&#xD;
             weeks, and the patient is off steroids.&#xD;
&#xD;
         14. Patient experienced ≥ Grade 3 immune-related AE with prior immunotherapy, with the&#xD;
             exception of non-clinically significant lab abnormalities.&#xD;
&#xD;
         15. Participant has a diagnosis of immunodeficiency or has received systemic steroid&#xD;
             therapy at a dose of &gt;10 prednisone or its equivalent or any other form of&#xD;
             immunosuppressive therapy within 7 days prior to initiating protocol therapy.&#xD;
&#xD;
         16. Participant has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg]&#xD;
             reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [qualitative]&#xD;
             is detected).&#xD;
&#xD;
         17. Participant has an active autoimmune disease that has required systemic treatment in&#xD;
             the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or&#xD;
             immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic&#xD;
             corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is&#xD;
             not considered a form of systemic treatment.&#xD;
&#xD;
         18. Participant must not have a history of interstitial lung disease.&#xD;
&#xD;
         19. Participant has received a live vaccine within 14 days of initiating protocol therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam ElNaggar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robin Patterson, RN</last_name>
    <phone>901-683-0055</phone>
    <phone_ext>63019</phone_ext>
    <email>rpatterson@westclinic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amanda Fletcher, RN</last_name>
    <phone>901-683-0055</phone>
    <phone_ext>61236</phone_ext>
    <email>afletcher@westclinic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>West Cancer Center</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 28, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2021</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West Cancer Center</investigator_affiliation>
    <investigator_full_name>Adam ElNaggar</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

